tbuckley/cabot-search huggingface dataset:
Bone Marrow Derived CD34+CXCR4+ Cells Maintain Viability, Mobility and Sterility up to 72 Hours and Are Compatible with Balloon Dilatation Catheters Used for Intra Coronary Artery Infusion; Pre-Clinical Development of a Pharmaceutical Grade Cell Therapy for Acute Myocardial Infarction (AMR-001).
Authors: Andrew L. Pecora, Robert A. Preti, Wai Shun Chan, Edmund K. Waller, Arshed Quyyumi, Douglas Vaughan, Thomas Moss
Journal: Blood (2007)
Splenectomy in Patients with Chronic Myeloid Leukemia or Myeloproliferative Diseases: Outcomes, Complications and Prognostic Implications.
Authors: Constantine S. Tam, Raphael E. Pollock, John Manning, Jorge Cortes, Katherine I. Lin, Deborah A. Thomas, Lingsha Zhou, Hagop Kantarjian, Srdan Verstovsek
Journal: Blood (2007)
Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma
Authors: Craig H. Moskowitz, Andres Forero-Torres, Bijal D. Shah, Ranjana Advani, Paul Hamlin, Stella Kim, Ana Kostic, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale
Journal: Blood (2014)
A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
Authors: A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Blay
Journal: Journal of Clinical Oncology (2011)

10072 Background: Doxorubicin remains the standard of care for STS. Its use has been limited due to bone marrow and cardiac toxicity, specially in elderly patients (pts). Doxorubicin GP-Pharm (Sarcodoxome)(DX-GP) is a non-pegylated liposomal formulation containing lipochromane-6. Previous Phase I study suggested activity and a low cardiac toxicity (CTOS 2008) Methods: Multicenter multinational Phase II prospective trial in advanced or metastatic STS pts aged ≥64 yr, to asses efficacy and safety of DX-GP in first line setting. Eligibility: ECOG ≤ 2, measurable disease by RECIST and acceptable hematologic, liver, renal and cardiac function. DX-GP 80 mg/m2 was administered IV over 60 minutes on day 1 every 3 weeks for a maximum of 6 cycles. Troponin, BNP, ECG and MUGA were performed every 2 cycles to evaluate cardiac function. An amendment (2009) expanded inclusion criteria to pts over than 45 years (thus only 4 pts <65 years old have been recruited). Results: From February 2007 to January 2010, 37 pts (13 male and 24 female) were included (12 retroperitoneum/trunk, 8 extremities, 4 uterine, 4 visceral). Median age 74 years (51-87). Non-resectable locally advanced 9, metastatic 28 pts. Nr of cycles: 116, mean 3(1-6). Grade 3/4 toxicities: Neutropenia 23 (62%), Leukopenia 10 (27%), febrile neutropenia 6 (16%), thrombopenia 4 (10%), anemia 2(5%) pts. Non-hematological toxicities were grade 3 asthenia 4 (10%) pts and grade II stomatitis and alopecia among others. 2 pts presented cardiac toxicity grade 1 and grade 5 respectively. Non cumulative cardiac toxicity. One treatment-related death. Efficacy (PR or SD) was seen in 8/26 (30%) evaluable pts. Median PFS was 3 (CI95% 1.9-7.4) months. Median survival time 14.4 (CI95% 6.3-27.1) months. Conclusions: DX-GP is a new liposomal DX that shows acceptable toxicity profile and efficacy at 80 mg/m2 in elderly pts with STS. Studies are needed in younger pts.
Predictive role of topoisomerase IIα, gp170, Bcl-2, tumor burden, and histology in neoadjuvant chemotherapy for soft tissue sarcomas of the extremities.
Authors: A. Comandone, P. Porrino, E. Berardengo, A. Linari, A. Boglione, C. Oliva, G. Gino, C. Faletti, P. Bergnolo, P. Pochettino, A. Bernardi, E. M. Brach del Prever, R. Piana
Journal: Journal of Clinical Oncology (2011)

10086 Background: Neoadjuvant chemotherapy (NACT) has a well established role in multidisciplinary treatment of soft tissue sarcomas (STS). Unfortunately no sure predictive factors have been identified in order to screen those patients who are going to benefit from NACT. Topoisomerase IIα (topo IIα) is a positive target for anthracyclines. Bcl-2 is a molecular target for alchilants. P-glycoprotein gp170 is a member of multidrug resistance (MDR) complex. This study aimed to evaluate if topo IIα, gp170, bcl-2, tumor burden and histology could predict the response to NACT in locally advanced STS of the extremities. Methods: Twenty-nine patients with STS of the extremities (median age 61 yrs, range 35-82) received a median of 3 cycles of Epirubicine and Ifosfamide as NACT. Topo IIα, gp170, bcl-2 were assessed by IHC either on pre-treatment biopsies and on post-treatment surgical specimens. Bioptical specimens were categorized in low and high expression according to a cut-off corresponding to the median value of the percentage of positive cells: 55% for topo IIα, 40% for bcl-2, 1% for gp170. Results were correlated with response rate estimated either with radiological (RECIST) criteria and pathological (responders must have > 90% tumor necrosis) criteria in an univariate analysis. Results: There were 7 responders (24.1%) and 22 non responders (75.9%) according to RECIST criteria. Tumor necrosis after NACT was > 90 % in 6 pts (20.7%). After NACT topo IIα decreased in 96% of tumors while gp170 increased in 89% of tumors. Univariate analysis identified a significant relationship between low expression of Bcl-2 on biopsies and pathological response (p .05). Tumor burden <10 cm and not-leiomyosarcoma histology were significant related with radiological response (p .023 and p .018). A conservative surgery was obtained in 86% of total pts. Conclusions: Bcl-2, tumor burden and histology predict NACT response in STS of the extremities. Topo IIα and gp170 variations after NACT can be explained with achievement of resistance by tumor cells.
Abstract 4622: Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers
Authors: Hyuna Sung, Howard H. Yang, Han Zhang, Qi Yang, Nan Hu, Ze-Zhong Tang, Hua Su, Lemin Wang, Chaoyu Wang, Ti Ding, Jin-Hu Fan, You-Lin Qiao, William Wheeler, Carol Giffen, Laurie Burdett, Zhaoming Wang, Maxwell P. Lee, Stephen J. Chanock, Sanford M. Dawsey, Neal D. Freedman, Christian C. Abnet, Alisa M. Goldstein, Kai Yu, Philip R. Taylor, Paula L. Hyland
Journal: Cancer Research (2015)

Abstract Background: Populations in north central China are at high risk for esophageal squamous cell carcinoma (ESCC) and gastric cancer (GC), and genetic variation in epigenetic machinery genes and pathways may contribute to this risk. Methods: We used the adaptive multilocus joint test (AdaJoint) to analyze 191 epigenetic genes involved in DNA methylation, chromatin remodeling, and microRNA biosynthesis in 1942 ESCC and 1758 GC cases [1126 cardia (GCA) and 632 non-cardia adenocarcinoma (GNCA)] and 2111 controls with Chinese ancestry. We examined the regulatory function of risk SNPs using in silico analyses and expression quantitative trait loci (eQTL) analysis in normal esophageal and gastric tissues. Results: Significant pathway-based associations were observed for the overall epigenetics (P = 3.4E-02) and chromatin remodeling (P = 3.9E-02) pathways with GCA risk, but not GC, GNCA or ESCC. SETD1B, CBX4, KAT5, ZGPAT, BTD, EED, SMARCD1, POLE3, AGO2, RING1 and MBD3L1 were associated with ESCC risk, and SUV42OH1, ASH1L, KAT5, JARID2, PRMT1, MBD3L1, SRRT, KDM5A, DROSHA and KAT6A were associated with GC risk overall (nominal P &amp;lt; 0.05). We identified EED rs10898459 (rho = -0.22, P = 2.9E-02) as a potential esophageal eQTL; DICER1 rs7157322 (rho = -0.42, P = 1.4E-02) and PPP1CA rs1790733 (rho = -0.41, P = 2.1E-03) as potential gastric eQTLs; and ASH1L rs12724079 and rs8179271 as potential gastric subtype eQTLs. Significance: As one of the first attempts to investigate epigenetic gene and pathway-level associations, our results suggest that chromatin remodeling and epigenetic pathways warrant further evaluation in relation to GC risk in other populations. Citation Format: Hyuna Sung, Howard H. Yang, Han Zhang, Qi Yang, Nan Hu, Ze-Zhong Tang, Hua Su, Lemin Wang, Chaoyu Wang, Ti Ding, Jin-Hu Fan, You-Lin Qiao, William Wheeler, Carol Giffen, Laurie Burdett, Zhaoming Wang, Maxwell P. Lee, Stephen J. Chanock, Sanford M. Dawsey, Neal D. Freedman, Christian C. Abnet, Alisa M. Goldstein, Kai Yu, Philip R. Taylor, Paula L. Hyland. Common genetic variants in epigenetic machinery genes and risk of upper gastrointestinal cancers. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4622. doi:10.1158/1538-7445.AM2015-4622
The Tumor Suppressors, MS4A3 and G0S2, Are Downregulated in CML Cells with BCR-ABL1 Kinase-Independent Resistance
Authors: Anna M. Eiring, Anupriya Agarwal, Jamshid S. Khorashad, Clinton C. Mason, David J. Anderson, Fan Yu, Hannah M. Redwine, Kevin C. Gantz, Kimberly R. Reynolds, Shannon K. McWeeney, Brian J. Druker, Thomas O'Hare, Michael W. Deininger
Journal: Blood (2014)
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome
Authors: Simona Colla, Derrick Ong, Yamini Ogoti, Matteo Marchesini, Nipun Mistry, Karen Clise-Dwyer, Paola Storti, Andrea Viale, Yue Wei, Nicola Giuliani, Hui Yang, Marianna D'Anca, Marcos R Estecio, Han Liang, Hagop M. Kantarjian, Alan Y. Wang, Lynda Chin, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Ronald DePinho
Journal: Blood (2014)
Quality assurance review center: Role in multi-institutional breast cancer trials.
Authors: J. Moni, H. T. Le-Petross, J. C. Boughey, F. Laurie, R. Hanusik, S. Howley, D. G. Logan, M. Bishop-Jodoin, R. M. Simmons, M. J. Ellis, K. Hunt, M. G. Cicchetti, S. Sioshansi, R. M. Quinlan, G. F. Whalen, T. J. Fitzgerald
Journal: Journal of Clinical Oncology (2011)

205 Background: Central review is an important trial management and validation tool. Multisite trials require data systems to accommodate diverse image acquisition and review. Breast cancer is challenging as its imaging objects are not always easily shared across departments. Quality Assurance Review Center (QARC) has a diverse portfolio of facile data acquisition and powerful informatics support that meets these needs. We report on the role of QARC in three of the current breast cancer trials from the American College of Surgeons Oncology Group. Methods: QARC data management system includes secure network infrastructure and a validated relational operating database (MAX). QARC has data acquisition/imaging re-distribution expertise for real time response reviews, response measuring tools and corresponding data archive for secondary reviews. MAX includes query ability; records link to digital information. QARC underwent systematic information systems validation process for 21 CFR Part 11. DICOM/non-DICOM files are stored in the QARC PACS. On-site/remote reviewers use MAX to retrieve, view, annotate and save images. Data extracted is securely sent to partner statistical centers. Results: In Z1031, a neoadjuvant endocrine therapy trial, all of the mammographic exams are archived at QARC. For Z1071, a sentinel lymph node trial, pre- and post-treatment ultrasound (US) images of 321 patients were remotely reviewed. For Z1072, the cryoablation US, pre and post-cryoablation MRI for 40 of 47 cases were remotely archived, retrieved and transferred to investigator workstation for post-processing and review. The other 7 patients did not have evaluable imaging studies. In all three trials, the costs of shipping hardcopies of exams and travel to QARC for central review functions were eliminated. Conclusions: QARC data management systems provide diverse informatics supports for multi-institutional trials, ranging from archives of images, provide remote access and download of data, and central review. The vibrant informatics supports meet the growing needs of clinical trials. Future directions include radiation field review for breast cancer trials and the incorporation of pathology microarray analysis as DICOM objects.
Detecting Drugs That Cause Thrombocytopenia: A Comparison of Three Methods: Tests for Drug-Dependent Anti-Platelet Antibodies (DDab), Published Case Reports, and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.
Authors: Xiaoning Li, Richard H. Aster, Brian R. Curtis, Daniel W. Bougie, Sara K. Vesely, James N. George
Journal: Blood (2007)
Phase II open, single-arm trial: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced triple-negative breast cancer.
Authors: A. Alvarado Miranda, F. U. Lara Medina, C. Arce, N. Castañeda-Soto, C. Cano Blanco, J. L. Aguilar Ponce, E. Bargallo Rocha, V. Perez-Sanchez
Journal: Journal of Clinical Oncology (2011)

1135 Background: Cisplatin has shown antitumor activity in breast cancer, and shows synergy with paclitaxel and antitumor activity in anthracycline-resistant breast tumors. In triple negative tumors, neoadjuvant cisplatin has reached pCR since 22-85%. The primary endpoint of this study was to evaluate the efficacy in terms of pCR with the use of doxorubicin/cisplatin followed by weekly paclitaxel/cisplatin. Secondary endpoints was to evaluate safety profile and disease free survival. Methods: We conducted open, single arm, phase II trial. We included patients with operable o locally advanced breast cancer (T2-T4, N0-3, M0), triple negative (according local pathologist), with good performance status (ECOG 0-1), with normal hepatic, hematologic and renal function. Protocol was approved by local ethics committee. Results: We included 44 patients. The median age at diagnosis was 45 years-old (range 26-76), with median tumor size of 6 cm (range 2-20 cm), 84% of this tumors were poorly differentiated. Overall clinical response was reached in 62% of cases (22% complete response and 40% partial response), complete pathologic response (breast and axilla) was founded in 34% of cases. The main non-hematologic toxicity was nausea and vomiting, and hematologic toxicity was neutropenia, leucopenia and anemia. Conclusions: Addition of cisplatin to doxorubicin and paclitaxel is well-tolerated with no significant increase in toxicity. The 34% of pCR observed appears similar to other regimens without cisplatin. We need to identify subgroups of patients responders to cisplatin.
Phase I study of high-dose interleukin (HD-IL2) and sorafenib in patients with metastatic clear cell renal cell carcinoma (RCC) and melanoma.
Authors: E. T. Lam, G. Lesinski, A. Mortazavi, K. L. Kendra, W. E. Carson, S. Tahiri, R. Liersemann, S. K. Clinton, T. Olencki, J. P. Monk
Journal: Journal of Clinical Oncology (2011)

337 Background: HD-IL2 has demonstrated activity for immune therapy of RCC and melanoma. Sorafenib is a multitargeted kinase inhibitor with antiangiogenic activity and may also modulate antitumor immunity. This ongoing phase I study assesses the safety, tolerability, dose-limiting toxicity (DLT), and maximum tolerated dose of the combination of HD-IL2 and sorafenib in patients with unresectable or metastatic clear cell RCC and melanoma. Methods: Eligible patients with ECOG PS 0-1, adequate organ function, and favorable or intermediate Motzer status (RCC patients) received up to two series of therapy. Each 82-day series consisted of two cycles of bolus HD-IL2 and 8 weeks of sorafenib. HD-IL2 (600,000 IU/kg IV q8h x 8-12 doses) was given on days 1-5 (cycle 1) and 15-20 (cycle 2). Sorafenib was given on days 29-82 and discontinued 48-72 hours prior to the next series. Dosing levels for sorafenib were (1) 200mg daily, (2) 200mg BID, (3) 200mg qAM and 400mg qPM, and (4) 400mg BID. Patients who achieved stable disease (SD), partial response (PR), or complete response (CR) after Series 1 proceeded to Series 2. Results: Fourteen patients (8 RCC, 6 melanoma) have been treated. Nine patients completed Series 1 (5 patients came off study due to poor tolerance of HD-IL2, prior to receiving sorafenib). Six patients had SD or better (3 PR, 3 SD) after Series 1. Of these, five have completed Series 2 and one patient progressed during sorafenib treatment in the second series. No DLTs were observed at the first 3 dose levels. All observed grade 3 and 4 AEs were transient and attributable to the known toxicities of HD-IL2 or sorafenib, and were not considered DLT. Adverse events occurring more frequently in Series 2 (HD-IL2 after sorafenib) included proteinuria and dry skin. One death occurred in a patient with melanoma who received only the first cycle of HD- IL2 (never received sorafenib) and one week later experienced sudden death at home, an event reported as possibly related to the HD-IL2. Conclusions: No DLT was seen in this study of HD-IL2 and sorafenib and the toxicity was predictable and manageable. Both RCC and melanoma patients experienced PR and SD, but not CR. Enrollment to cohort 4 is ongoing. [Table: see text]
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study
Authors: Ruth Wittoek, Philippe Carron, Bieke Lambert, Paulien Meersseman, Gust Verbruggen, Filip Van den Bosch, Dirk Elewaut
Journal: Annals of the Rheumatic Diseases (2016)

Erosive hand osteoarthritis (OA) of the interphalangeal (IP) joints is characterised by a more pronounced inflammatory burden of disease.1 Whether it is a subset of hand OA or just a radiographic phase remains a matter of debate. The pathogenesis of erosive OA is not yet understood, but articular cartilage degeneration and subchondral bone resorption are some of the major characteristics. In general, several cytokine-driven pathways such as receptor activator of nuclear factor κB, interleukin-1 and tumour necrosis factor (TNF) alpha are involved at the level of the subchondral bone-inducing dynamic morphological changes.2–4 In post hoc analyses in two recent placebo-controlled pilot studies in erosive OA, it was shown that adalimumab and etanercept were able to diminish structural progression after 1 year of treatment in a subgroup of patients who showed soft tissue swelling at baseline.5 ,6

We hypothesised …
Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status
Authors: Asher Chanan-Khan, Meletios A Dimopoulos, Donna M. Weber, Andrew Spencer, Michel Attal, Andrew Belch, Alessandro Corso, Tommy Fu, Jerome B. Zeldis, Marta Olesnyckyj, Robert D. Knight, Sagar Lonial
Journal: Blood (2008)
A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial
Authors: David W Scott, Fong Chun Chan, Fangxin Hong, Sanja Rogic, King Tan, Barbara Meissner, Pedro Farinha, Sandra J. Horning, Richard I Fisher, Nancy L. Bartlett, Lois E Shepherd, Joseph M. Connors, Aida B. de Sousa, Brad S. Kahl, Leo I. Gordon, Christian Steidl, Randy D. Gascoyne
Journal: Blood (2011)
Significantly Lower Cryopreservation Volumes for PBSC Collections Using Spectra Optia® Version 5 Software Compared with the MNC Setting on COBE® Spectra, Particularly When Using Plerixafor for Mobilisation
Authors: Mhairi Copland, Michael Alcorn, Daniela Patton, Allyson Doig, Elizabeth Farrell, Colette Currie, Joy E Sinclair, Anne Parker, Kenneth W Douglas
Journal: Blood (2010)
A combination of sorafenib, nelfinavir, and sirolimus in a patient with progressive metastatic synovial sarcoma after chemotherapy.
Authors: A. M. Negandhi, M. M. Milhem
Journal: Journal of Clinical Oncology (2011)

e20531 Background: We report the case of a 34-year-old man with a poorly differentiated synovial sarcoma localized to the kidney. The tumor was positive for the SYT-SSX2 fusion transcript and negative for EWS-FL11 and EWS-ERG. He received 6 cycles of adriamycin and ifosfamide after nephrectomy. 1 year after completing chemotherapy, metastatic disease was found in the form of lung nodules. This was treated with metastatectomy. New lung nodules were noted 1 month after surgery. 2 cycles of gemcitabine and docetaxel were given, but his disease continued to progress, leading to another metastatectomy. 6 months later, metastatic disease was again noted in the lungs. Sorafenib was initiated, and nelfinavir was added 1 month later. 2 months after starting sorafenib, CT chest showed a decrease in the size of 1 lung nodule with otherwise stable disease. 6 months after starting sorafenib, he was found to have progressive disease by CT and sirolimus was added. Dose adjustments were made for hand-foot skin reaction and diarrhea. Therapy was interrupted for a febrile illness during which progressive disease was noted. His disease remained stable once triple therapy was restarted. Methods: The RAF/MEK/ERK and mTOR/AKT pathways are implicated in the proliferation of synovial sarcoma. Due to cross talk between these pathways in which one is up regulated when the other is blocked and the up regulation of Akt secondary to mTOR inhibition, we treated our patient with a combination of therapy that would minimize pathway activation by way of these feedback loops. Informed consent was obtained from the patient. Results: Disease stabilization was achieved with a novel combination of a multi-kinase inhibitor, an AKT inhibitor, and an mTOR inhibitor in this patient with metastatic synovial sarcoma. The patient is doing well with tolerable side effects 21 months after initiating moleculary targeted therapy and 34 months after metastatic disease was found. Conclusions: A combination of moleculary targeted therapy may be useful in the treatment of metastatic synovial sarcoma which has progressed after chemotherapy.
Erythropoietic Protoporphyric Red Blood Cells Are Resistant to the Growth of Malarial Parasites
Authors: Brendan John McMorran, Clare M Smith, Ante Jerkovic, Hervé Puy, Ingrid Winship, Jean-Charles Deybach, Laurent Gouya, Giel van Dooren, Christopher Dean Goodman, Angelika Sturm, Hana Manceau, Geoffrey Ian McFadden, Peter David, Odile Mercereau-Puijalon, Gaetan Burgio, Simon J Foote
Journal: Blood (2014)